Arivarasan Karunamurthy

Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (4)

Supplementary Methods S1. Gene Expression Profiling (GEP), Peripheral Blood, Multiplex Serum Cytokine Analysis, Multicolor Flow Cytometry, Survival Analysis, LASSO Signature Training and Testing.

Year:

2025

Purpose: Ipilimumab (IPI) improved outcomes for patients with high-risk melanoma compared with IFN-α2b in E1609, a phase III adjuvant trial. We hypothesized that combining candidate immune biomarkers in both tumor and circulating blood could generate a superior predictive biomarker signature. Experimental Design: We conducted gene expression profiling on baseline tumors of patients treated with IPI and IFN. We also performed multicolor flow cytometry to compare cellular marker expression on thawed peripheral blood mononuclear cells and Luminex multiplex assay to measure serum biomarkers. We tested the expression levels of 31 genes and 40 circulating biomarkers in relation to survival outcomes. We then developed two separate multivariate Least Absolute Shrinkage and Selection Operator (LASSO) Cox regression models followed by integrative modeling of risk prediction using the prioritized biomarkers. Results: In blood, enriched populations of CXCR3 + CD4 + T cells, CXCR3 + CD8 + T cells, CTLA4 + IFN-γ + CD8 + T cells, and higher levels of CCL3 and CXCL11 were associated with significantly improved overall survival and relapse-free survival, whereas high levels of CTLA4 + regulatory T cells (CD3 + CD4 + CD25hi + CD152 + ) and monocytic myeloid-derived suppressor cells (Lin-CD33 + HLA-Dr lo CD14 + CD15 + ) correlated with worse overall survival and relapse-free survival. In tumor, CXCL9, CD8A, CXCL10, and inositol polyphosphate-5-phosphatase D were identified as tier-1 ( P P Conclusions: Integrating candidate blood and tumor immune-related biomarkers generated a baseline signature that maximizes the prediction of immunotherapeutic benefits in reference to the compartmental biomarker signatures.

Year:

2025

Supplementary Figure S5. Kaplan-Meier overall survival (OS) and recurrence-free survival (RFS) curves of 4 prioritized high-risk and low-risk features determined by the Cox proportional hazards regression analysis.

Year:

2025

Year:

2022

Collaborators (9)

Vernon Sondak

Chair

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Issam El Naqa

Chair

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Lisa Butterfield

Distinguished Scientist

University of California, San Francisco

UNITED STATES
View details

John Kirkwood

Distinguished Service Professor of Medicine

University of Pittsburgh

UNITED STATES
View details

Walter Storkus

Professor

University of Pittsburgh

UNITED STATES
View details

William LaFramboise

Chief Genomics Technology Officer, Professor

Alleghgeny Health Network

UNITED STATES
View details

Timothy Shaw

Assistant Member/Professor

Moffitt Cancer Center

UNITED STATES
View details

Ahmad Tarhini

Senior Member, Professor

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Dung-Tsa Chen

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details